Trastuzumab - 20mg/ml in Histidine buffer (lyophilised powder)

CAS : 180288-69-1

Ref. 3D-BT184541

Informations sur le produit

• Nom: Trastuzumab - 20mg/ml in Histidine buffer (lyophilised powder)
• Synonymes: HerceptinImmunoglobulin G1Hervycta
• Marque: Biosynth
• Description: Trastuzumab is a humanised immunoglobulin G1 monoclonal antibody against human epidermal growth factor receptor 2 (HER2), used in breast cancer treatments. Some potential extracellular and intracellular antitumor mechanisms of trastuzumab have been proposed, including activation of antibody-dependent cellular cytotoxicity, inhibition of extracellular domain cleavage, abrogation of intracellular signalling, reduction of angiogenesis and decreased DNA repair that result in tumour cell stasis and/or death. Its drug conjugate, trastuzumab deruxtecan (T-DXd), is used in the clinical therapy for pretreated HER2-mutant non-small cell lung cancer (NSCLC).